south-korea8217s-celltrion-aims-to-set-up-china-jv-within-first-half-of-2019-chairman

South Korea’s Celltrion aims to set up China JV within first half of 2019: chairman

© Reuters. The logo of Celltrion is seen at company's headquarters in Incheon© Reuters. The logo of Celltrion is seen at company's headquarters in Incheon

SEOUL (Reuters) - South Korean drugmaker Celltrion Inc (KS:) aims to set up a joint venture in China within the first half of this year, and begin selling products in the country next year, its chairman said on Sunday.

"Since last year, we've been pushing on with a plan to set up a joint venture in China," Chairman Seo Jung Jin told reporters. The firm has been in talks with several Chinese companies, he said, declining to elaborate.

Celltrion sells drugs known as biosimilars, mainly to Europe and the United States.

It is South Korea's third-largest company by market value, after Samsung Electronics Co Ltd (KS:) and chipmaker SK Hynix Inc (KS:), according to the Korea Stock Exchange.

On Friday, it said it would build a third domestic plant and is continuing to review potential manufacturing sites overseas.

Disclaimer: Fusion Media

would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.